All pulse issues

Daily Healthtech Pulse

Healthtech Pulse: Prior Auth Is Becoming Infrastructure (and the Winners Will Own the Workflow, Not the API)

A public market brief on why electronic prior authorization is no longer a compliance project: CMS is forcing cross-ecosystem integration, AI in utilization management is colliding with consumer protections, and “proof + auditability” is becoming the real product for regulated healthcare software.

The headline isn’t that prior auth is getting digitized. The signal is that prior auth is turning into infrastructure: a real-time integration surface that links payers, providers, and EHRs—and exposes who actually controls the workflow when money and medical necessity collide.

Founders and operators should stop treating prior auth as “a feature” and start treating it as an operating system problem: data quality, orchestration, human decision points, and defensible rationale. In the next 12–18 months, the differentiator won’t be who has a FHIR endpoint. It will be who can make the end-to-end loop work in production without creating regulatory, legal, or reputational blowback.

CMS just made prior auth a multi-party build, not a payer problem (and that changes who can win)

CMS’s early-adopter network for electronic prior authorization is a quiet but profound shift: it’s not asking payers to “be nicer.” It’s pulling providers, EHRs, and networks into the same room and treating prior auth like an ecosystem integration problem with real workflow ownership on the line.

Read it as a market structure move. When CMS says the next phase is about workflow gaps and technical handoffs, it’s admitting what everyone on the ground knows: standards don’t equal outcomes. A FHIR API can exist and still fail in production because the data is incomplete, the clinical narrative doesn’t map cleanly to policy logic, and the people doing the work don’t trust the automation.

The operator implication: the winner is the team that owns the “last mile” between policy and care delivery—routing, fallbacks, status visibility, and human escalation. That’s where time gets burned, where patients churn, and where CFOs feel margin erosion. The commercial wedge isn’t compliance; it’s reliability at scale.

AI is already inside claims review; the fight is moving to governance, consumer protections, and “who’s liable”

While the tech world still frames AI in healthcare as a clinical story, payers have been using automation in coverage decisions for years. The new tension is not “AI exists.” It’s what happens when AI gets applied to denial and approval logic at scale—and consumers, states, and Congress start asking for guardrails.

KFF’s read on AI in prior authorization and claims review highlights a messy reality: protections are fragmented, and policy moves can reshape the compliance surface overnight. If federal policy starts preempting state consumer protection laws, you can end up with faster deployment—but also more concentrated risk when something goes wrong.

This is where healthtech GTM gets non-obvious. If you sell into payer or delegated UM workflows, your product needs an answer for explainability, appealability, and auditability. “We use AI to speed decisions” is not a value prop—unless you can also show how the system prevents inappropriate denials, handles exceptions, and creates a defensible record when a decision is challenged.

“Proof” is becoming the product: FDA-cleared AI is a reminder that regulated adoption is an integration + evidence discipline

Bayesian Health’s FDA clearance for a continuous AI sepsis monitor matters beyond sepsis. It’s a real-world example of where the category is going: regulated AI that must survive evidence scrutiny, clinical integration, and operational monitoring—not just a demo.

In procurement terms, this is the pattern: leaders don’t buy “AI.” They buy reduced risk and improved outcomes with measurable performance. That requires integration into the existing system of record, clear escalation paths, and ongoing surveillance when the environment changes (workflow, patient mix, clinician behavior, documentation practices).

For founders building in adjacent administrative domains (utilization management, care navigation, clinical ops), the lesson is the same: treat evidence and governance as a first-class deliverable. The product is not the model—it’s the workflow that makes the model safe, predictable, and defensible.

The GTM wedge is shifting from “interoperability” to “operational outcomes”: reliability, cycle-time, and trust

The market is moving past “we support FHIR.” Everybody will check that box. The buyer question is: does anything actually change after implementation? Do authorizations move faster? Do clinicians spend less time chasing status? Do denials become predictable and reducible? Do you get a clean audit trail when someone asks why a decision happened?

That’s why CMS’s stance is important: it’s pushing the ecosystem toward production-grade workflows. This forces vendors to confront the parts they usually avoid—data normalization, exception handling, and operational ownership. The companies that win will be the ones that instrument the process and continuously improve it, not the ones that just ship interfaces.

Operator move: sell the operating loop. Build a narrative that ties integration to measurable business outcomes (cycle time, leakage, abandonment, avoidable utilization, admin cost) and includes governance by design. In regulated healthcare commercialization, trust is not a slogan—it’s a system behavior you can prove.

Operator actions

  • Treat prior auth as an end-to-end workflow, not an API project.
  • Build governance as a product surface: inputs, versions, overrides, audit trail.
  • Sell outcomes: cycle-time, status visibility, and exception handling—measured in production.
  • Assume policy risk: design for appeals, consumer protections, and defensible rationale.
  • If you use AI, ship monitoring and escalation like it’s part of the core product (because it is).

Sources used

Related on this site